Across TCGA pan-cancer cohorts, C6orf120 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C6orf120 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher C6orf120 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C6orf120 expression acts as an unfavorable survival marker.

ACC and BLCA are the cancer types where C6orf120 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
BLCA	DFS	Median	III,IV	0.163	0.572	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: C6orf120 tumor-vs-normal RNA expression · all C6orf120 data types